Discovers and develops innovative products and therapeutic options for specialty biopharmaceuticals. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 11% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1,485.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 49% of them.
No analyst target is on record for this company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
An investor who bought at the very peak is down 91% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $32K a year. A small number, but proof the product has real buyers.
A loss of $11.8M against $32K in annual sales.
The stock sits at $0.44. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, IBO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: IBO is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.